4.8 Article

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Journal

NATURE
Volume 476, Issue 7359, Pages 214-219

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nature10251

Keywords

-

Funding

  1. Wellcome Trust [085475/B/08/Z, 085475/Z/08/Z, 075491/Z/04/Z, 068545/Z/02]
  2. National Institutes of Health [AI076544, NS032830, NS049477, NS19142, NS049510, NS26799, NS43559, NS067305, CA104021, RR020092, RR024992, K23N/S048869]
  3. US National Multiple Sclerosis Society [RG 4201-A-1]
  4. Nancy Davis Foundation
  5. Cambridge NIHR Biomedical Research Centre
  6. UK Medical Research Council [G0700061, G0000934]
  7. Multiple Sclerosis Society of Great Britain and Northern Ireland [898/08]
  8. Wolfson Royal Society
  9. Peter Doherty fellowship
  10. Lagrange Fellowship
  11. Harry Weaver Neuroscience Scholarships
  12. Australian National Health and Medical Research Council (NHMRC)
  13. Australian Research Council
  14. JHH Charitable Trust
  15. Multiple Sclerosis Research Australia
  16. Health Research Council New Zealand
  17. National MS Society of New Zealand
  18. Wetenschappelijk Onderzoek Multiple Sclerose
  19. Bayer Chair on Fundamental Genetic Research
  20. Biogen Idec Chair Translational Research in Multiple Sclerosis
  21. FWO-Vlaanderen
  22. Belgian Neurological Society
  23. Danish Multiple Sclerosis Society
  24. Neuropromise EU [LSHM-CT-2005-018637]
  25. Center of Excellence for Disease Genetics of the Academy of Finland
  26. Sigrid Juselius Foundation
  27. Helsinki University Central Hospital Research Foundation
  28. Bundesministerium fur Bildung und Technologie (KKNMS consortium Control MS)
  29. Deutsche Forschungsgemeinschaft
  30. Institut National de la Sante et de la Recherche Medicale (INSERM)
  31. Association pour la Recherche sur la Sclerose En Plaques (ARSEP)
  32. Association Francaise contre les Myopathies (AFM)
  33. Italian Foundation for Multiple Sclerosis [2002/R/40, 2005/R/10, 2008/R/11, 2008/R/15]
  34. Italian Ministry of Health [Giovani Ricercatori 2007-D.lgs 502/92]
  35. Regione Piemonte [2003, 2004, 2008, 2009]
  36. CRT Foundation
  37. Turin
  38. Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre
  39. Norwegian MS Register and Biobank
  40. Research Council of Norway
  41. South-Eastern and Western Norway regional Health Authories
  42. Ulleval University Hospital Scientific Advisory Council
  43. Haukeland University Hospital
  44. Amici Centro Sclerosi Multipla del San Raffaele (ACESM)
  45. Association of British Neurologists
  46. Spanish Ministry of Health [FISPI060117]
  47. Bibbi and Niels Jensens Foundation
  48. Montel Williams foundation
  49. Hjarnfonden and Swedish medical research council [8691]
  50. Stockholm County Council [562183]
  51. Swedish Council for Working life and Social Research
  52. Gemeinnutzige Hertie Stiftung
  53. Northern California Kaiser Permanente members and Polpharma Foundation
  54. Washington University Institute of Clinical and Translational Sciences-Brain, Behavioral and Performance Unit
  55. German Ministry of Education and Research
  56. Helmholtz Zentrum Munchen-National Research Center
  57. German National Genome Research Network (NGFN)
  58. LMUinnovativ
  59. Knut and Alice Wallenberg Foundation
  60. Children's Hospital of Philadelphia
  61. Agency for Science & Technology and Research of Singapore
  62. Susan G. Komen Breast Cancer Foundation
  63. Medical Research Council [G0700061, G0100594, G0901461, G19/2, G9817803B, G0901310, G0400017, MC_EX_G0800860, G0801418B] Funding Source: researchfish
  64. National Institute for Health Research [NF-SI-0507-10379, PDA/02/06/016] Funding Source: researchfish
  65. Parkinson's UK [J-0804] Funding Source: researchfish
  66. MRC [G0901310, G0901461, G0100594, G19/2, MC_EX_G0800860, G0700061, G0400017] Funding Source: UKRI

Ask authors/readers for more resources

Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability(1). Epidemiological studies have shown that genetic factors are primarily responsible for the substantially increased frequency of the disease seen in the relatives of affected individuals(2,3), and systematic attempts to identify linkage in multiplex families have confirmed that variation within the major histocompatibility complex (MHC) exerts the greatest individual effect on risk(4). Modestly powered genome-wide association studies (GWAS)(5-10) have enabled more than 20 additional risk loci to be identified and have shown that multiple variants exerting modest individual effects have a key role in disease susceptibility(11). Most of the genetic architecture underlying susceptibility to the disease remains to be defined and is anticipated to require the analysis of sample sizes that are beyond the numbers currently available to individual research groups. In a collaborative GWAS involving 9,772 cases of European descent collected by 23 research groups working in 15 different countries, we have replicated almost all of the previously suggested associations and identified at least a further 29 novel susceptibility loci. Within the MHC we have refined the identity of the HLA-DRB1 risk alleles and confirmed that variation in the HLA-A gene underlies the independent protective effect attributable to the class I region. Immunologically relevant genes are significantly overrepresented among those mapping close to the identified loci and particularly implicate T-helper-cell differentiation in the pathogenesis of multiple sclerosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available